BridgeBio Pharma, Inc.
BBIO
$38.62
$0.280.73%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -44.76% | 237.08% | -33.22% | 32.11% | 11,461.88% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -44.76% | 237.08% | -33.22% | 32.11% | 11,461.88% |
| Cost of Revenue | 341.30% | 248.49% | 0.00% | -0.17% | -8.14% |
| Gross Profit | -45.85% | 231.12% | -38.91% | 50.67% | 17,816.77% |
| SG&A Expenses | 61.63% | 99.19% | 92.36% | 64.78% | 111.54% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.30% | 27.36% | 17.55% | 21.22% | 66.41% |
| Operating Income | -2,873.23% | -25.29% | -18.87% | -21.10% | 103.05% |
| Income Before Tax | -369.05% | -56.31% | 8.49% | 52.99% | 74.67% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -369.05% | -56.98% | 8.49% | 52.99% | 74.67% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 131.57% | 7.29% | -11.05% | -25.53% | -63.35% |
| Net Income | -375.41% | -57.63% | 8.45% | 53.48% | 74.87% |
| EBIT | -2,873.23% | -25.29% | -18.87% | -21.10% | 103.05% |
| EBITDA | -2,020.17% | -25.64% | -19.14% | -21.39% | 104.41% |
| EPS Basic | -346.73% | -45.16% | 20.69% | 60.19% | 78.53% |
| Normalized Basic EPS | -959.38% | -26.71% | -6.12% | -8.62% | 91.89% |
| EPS Diluted | -346.73% | -45.16% | 20.69% | 60.19% | 78.53% |
| Normalized Diluted EPS | -959.38% | -26.71% | -6.12% | -8.62% | 91.89% |
| Average Basic Shares Outstanding | 6.40% | 8.58% | 15.43% | 16.85% | 17.07% |
| Average Diluted Shares Outstanding | 6.40% | 8.58% | 15.43% | 16.85% | 17.07% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |